(Q45374247)

13 December 2017

title

Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer (English)

1 reference

13 December 2017

1 reference

1 reference

2

Yoshinori Ito

1 reference

13 December 2017

3

Shunji Takahashi

1 reference

13 December 2017

12

Kiyohiko Hatake

1 reference

13 December 2017

Yoshimi Ide

1

1 reference

13 December 2017

Nahomi Tokudome

4

1 reference

13 December 2017

Kokoro Kobayashi

5

1 reference

13 December 2017

Tsutomu Sugihara

6

1 reference

13 December 2017

Masaya Hattori

7

1 reference

13 December 2017

Masahiro Yokoyama

8

1 reference

13 December 2017

Akira Uchiyama

9

1 reference

13 December 2017

Kazuaki Inoue

10

1 reference

13 December 2017

Norio Sakurai

11

1 reference

13 December 2017

publication date

24 July 2010

1 reference

13 December 2017

1 reference

13 December 2017

volume

20

1 reference

13 December 2017

issue

4

1 reference

13 December 2017

page(s)

367-370

1 reference

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0213-X

10.1007/S12282-010-0213-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

13 December 2017

1019473216

0 references

1 reference